Method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride

Through the gradient elution procedure of high performance liquid chromatography, the problem of isopropyl acetone and porone residue detection in gemcitabine hydrochloride was solved, effectively controlling the quality of the drug, ensuring the safety and quality of the drug.

CN118937508APending Publication Date: 2024-11-12FUAN PHARM GRP NINGBO TIANHENG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410773721.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-17
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art cannot effectively detect the residues of isopropyl acetone and porone in gemcitabine hydrochloride, affecting drug quality control.

Method used

High performance liquid chromatography is used, using water and acetonitrile as mobile phases, and through a gradient elution program, combined with appropriate columns and column gentle detection wavelengths, the effective separation and quantitative detection of isopropyl acetone and porone are achieved.

Benefits of technology

The detection efficiency of isopropyl acetone and porone in gemcitabine hydrochloride is improved, the quality of drug raw materials and preparations is ensured, and effective monitoring of mutagenic impurities is achieved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937508A_ABST
    Figure CN118937508A_ABST
Patent Text Reader

Abstract

The invention relates to a method for determining the residues of mesityl oxide and phorone in gemcitabine hydrochloride, and provides a method for determining the residues of mesityl oxide and phorone in gemcitabine hydrochloride, which adopts a high performance liquid chromatograph, takes water and acetonitrile as mobile phases, and determines the residues of mesityl oxide and phorone in gemcitabine hydrochloride by adjusting the gradient elution procedure of the mobile phases. According to the present invention, the gemcitabine hydrochloride is used as the raw material, and the appropriate chromatographic column, the appropriate column temperature detection wavelength is selected, such that the effective separation of the mutagenic impurities such as the mesityl oxide and the phorone in the gemcitabine hydrochloride is achieved, and the mesityl oxide and the phorone in the gemcitabine hydrochloride can be efficiently and rapidly subjected to the quantitative detection so as to improve the quality control of the gemcitabine hydrochloride bulk drug and the preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of compound analysis and detection, and in particular to a method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride. Background Art

[0002] Gemcitabine is a pyrimidine antimetabolite, which is metabolized into active diphosphate (dFdCDP) and triphosphate nucleoside (dFdCTP) by nucleoside kinase in cells. dFdCDP and dFdCTP achieve the cytotoxic effect of gemcitabine by inhibiting DNA synthesis. The main clinical indications of gemcitabine hydrochloride are non-small cell lung cancer, pancreatic cancer, biliary tract cancer, urothelial carcinoma, inoperable or recurrent breast cancer, ovarian cancer aggravated after cancer chemotherapy, and recurrent or refractory malignant lymphoma.

[0003] Mesityl oxide, CAS No. 141-79-7, chemical name methyl isobutylene ketone, 4-methyl-3-pentene-2-one, is an important organic synthesis intermediate.

[0004]

[0005] Isopropyl acetate is mainly used in medicines, fine chemicals and pesticides. It can be used as a medium boiling point solvent and as a solvent for nitrocellulose and various resins, especially vinyl resins, as well as spray paint.

[0006] Phorone, CAS No. 504-20-1, chemical name 3,5,5-trimethyl-2-cyclohexene-1-one,

[0007]

[0008] Phorone is obtained by catalytic condensation and dehydration of acetone. It is also an important organic chemical raw material. It is used as a solvent and is also used in the production of synthetic resins, fibers, pharmaceutical intermediates, lubricant additives, and deodorants.

[0009] Organic solvents are required in the production process of gemcitabine hydrochloride. Acetone is a commonly used organic solvent in chemical synthesis, and the salt formation of compounds with acids is also a commonly used technique in pharmaceutical chemistry. Acetone will polymerize in a hydrochloric acid or hydrogen chloride vapor environment, and its dimerization product is mainly mesityl oxide, and the main product of the trimerization reaction is phorone. If acetone is used as a solvent or refining solvent in the production process of gemcitabine hydrochloride, mesityl oxide and phorone are likely to be generated. Both are unsaturated ketone structures and contain genotoxic carcinogenic warning structures. Therefore, it is necessary to pay attention to the residues of potential mutagenic impurities mesityl oxide and phorone in gemcitabine hydrochloride.

[0010] Existing literatures mostly use gas chromatography to determine mesityl oxide and phorone, and there is currently no detection technology for mesityl oxide and phorone in gemcitabine hydrochloride raw materials and preparations. Therefore, it is very necessary to develop a detection technology that can effectively detect mesityl oxide and phorone in gemcitabine hydrochloride, thereby ensuring the quality of gemcitabine hydrochloride raw materials and preparations. Summary of the invention

[0011] The technical problem to be solved by the present invention is to provide a method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride with strong specificity and high detection ability in view of the current status of the prior art. The method can simultaneously detect the residues of mesityl oxide and phorone in gemcitabine hydrochloride, thereby ensuring the quality of gemcitabine hydrochloride raw materials and preparations, and improving the actual production detection efficiency.

[0012] The technical solution adopted by the present invention to solve the above technical problems is:

[0013] A method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride is implemented by high performance liquid chromatography with water and acetonitrile as mobile phases for gradient elution, and is achieved by the following steps:

[0014] (1) Chromatographic conditions:

[0015] A chromatographic column using octadecylsilane bonded silica as a filler;

[0016] Water was used as mobile phase A and acetonitrile as mobile phase B, and the elution was performed by a gradient elution program;

[0017] (2) Solution preparation:

[0018] Reference solution: weigh mesityl oxide and phorone reference substances, add solvent to make a solution containing 0.005 μg to 0.5 μg of phorone and mesityl oxide per 1 mL;

[0019] Test solution: Take gemcitabine hydrochloride and add solvent to make a solution of 1 mg / ml to 50 mg / ml.

[0020] Preferably, the chromatographic column is an Inertsil ODS-3, 4.6 mm×250 mm, 5 μm or an Inertsil ODS-3v, 4.6 mm×250 mm, 5 μm.

[0021] Preferably, the procedure of the gradient elution is:

[0022]

[0024] Preferably, the detection column temperature is 15°C to 40°C, the flow rate is 0.5ml / min to 2ml / min, the detection wavelength is 200nm to 300nm, and the injection volume is 10μl to 100μl.

[0025] Preferably, the solvent used to prepare the reference solution and the test solution is acetonitrile with a volume concentration of 10% to 90%.

[0026] More preferably, the concentration of the reference solution is 0.05 μg / ml, and the concentration of the test solution is 10 mg / ml.

[0027] Compared with the prior art, the invention has the advantages that: the invention provides a method for determining the residues of mesityl oxide and phorone in gemcitabine hydrochloride, adopts a high performance liquid chromatograph, takes water and acetonitrile as mobile phases, adjusts the mobile phase gradient elution program, and selects a suitable chromatographic column, column temperature and detection wavelength, so as to achieve effective separation of mutagenic impurities mesityl oxide and phorone in gemcitabine hydrochloride, and can efficiently and quickly perform quantitative detection of mesityl oxide and phorone in gemcitabine hydrochloride, thereby improving the quality control of gemcitabine hydrochloride raw materials and preparations. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The system applicability solution spectrum in Example 1 of the present invention;

[0029] Figure 2 The system applicability solution spectrum in Example 2 of the present invention;

[0030] Figure 3 This is the blank solution spectrum in Example 3 of the present invention;

[0031] Figure 4 The system applicability solution spectrum in Example 3 of the present invention;

[0032] Figure 5 This is the sample solution spectrum in Example 3 of the present invention. DETAILED DESCRIPTION

[0033] The present invention is further described in detail below with reference to the accompanying drawings.

[0034] The instruments and reagents used in the embodiments of the present invention are as follows:

[0035] High performance liquid chromatograph: Agilent 1260;

[0036] Gemcitabine hydrochloride: Ningbo Tianheng Pharmaceutical Co., Ltd., Fu'an Pharmaceutical Group;

[0037] Acetonitrile: chromatographic grade, Tianjin Concord Technology Co., Ltd.;

[0038] Mesityl oxide: Aladdin, 96.37%;

[0039] Phorone: Shanghai BiDe Pharmaceutical Technology Co., Ltd., 98%.

[0040] Embodiment 1:

[0041] The present embodiment adopts HPLC method to determine mesityl oxide and phorone residues in gemcitabine hydrochloride, comprising the following steps:

[0042] Preparation of system suitability solution: Take gemcitabine hydrochloride test sample, mesityl oxide and phorone, add solvent (60% acetonitrile) to make a solution containing 10 mg of gemcitabine hydrochloride, 0.05 μg of phorone and mesityl oxide per 1 ml;

[0043] High performance liquid chromatography was used for sample injection and detection, and the chromatographic conditions were as follows:

[0044] Chromatographic column: a chromatographic column with octadecylsilane bonded silica as a filler. Inertsil ODS-3, 4.6 mm × 250 mm, 5 μm, was selected in this embodiment;

[0045] Mobile phase A: water; Mobile phase B: acetonitrile;

[0046] Gradient elution program:

[0047]

[0048] Flow rate: 1.0ml / min;

[0049] Column temperature: 30°C;

[0050] Detection wavelength: 245nm;

[0051] Injection volume: 50 μl;

[0052] Take the system suitability solution and inject it according to the above chromatographic conditions for testing. Figure 1 The peak of mesityl oxide is at 5.173 min, and the peak of phorone is at 11.039 min. The results show that mesityl oxide and phorone can be effectively separated in this embodiment with good specificity.

[0053] Embodiment 2:

[0054] The present embodiment adopts HPLC method to determine mesityl oxide and phorone residues in gemcitabine hydrochloride, comprising the following steps:

[0055] Preparation of system suitability solution: Take gemcitabine hydrochloride test sample, mesityl oxide and phorone, add solvent (60% acetonitrile) to make a solution containing 10 mg of gemcitabine hydrochloride, 0.05 μg of phorone and mesityl oxide per 1 ml.

[0056] High performance liquid chromatography was used for sample injection and detection, and the chromatographic conditions were as follows:

[0057] Chromatographic column: a chromatographic column with octadecylsilane bonded silica as a filler, in this embodiment, Welch XtimateC18, 4.6mm×250mm, 5μm;

[0058] Mobile phase A: water; Mobile phase B: acetonitrile;

[0059] Gradient elution program:

[0060]

[0061]

[0062] Flow rate: 1.0ml / min;

[0063] Column temperature: 30°C;

[0064] Detection wavelength: 245nm;

[0065] Injection volume: 50 μl;

[0066] Take the system suitability solution and inject it according to the above chromatographic conditions for testing. Figure 2 The peak of mesityl oxide is at 3.996 min, and the peak of phorone is at 7.478 min. The results show that mesityl oxide and phorone can be effectively separated in this embodiment with good specificity.

[0067] Embodiment 3:

[0068] The present embodiment adopts HPLC method to determine mesityl oxide and phorone residues in gemcitabine hydrochloride, comprising the following steps:

[0069] Blank: 50% acetonitrile;

[0070] Reference stock solution: Take mesityl oxide and phorone and add blank solvent to make a solution containing 0.5 μg of phorone and mesityl oxide per 1 ml.

[0071] Preparation of system suitability solution: Take 0.1 g of gemcitabine hydrochloride test sample, pipette appropriate amount of mesityl oxide and phorone stock solution, add solvent to make a solution containing 10 mg of gemcitabine hydrochloride, 0.05 μg of phorone and mesityl oxide per 1 ml.

[0072] Test solution: Place 0.1 g of gemcitabine hydrochloride test sample into a 10 ml volumetric flask and add solvent to make a solution containing 10 mg of gemcitabine hydrochloride per 1 ml.

[0073] High performance liquid chromatography was used for sample injection and detection, and the chromatographic conditions were as follows:

[0074] Chromatographic column: a chromatographic column with octadecylsilane bonded silica as a filler. Inertsil ODS-3, 4.6 mm × 250 mm, 5 μm, was selected in this embodiment;

[0075] Mobile phase A: water; Mobile phase B: acetonitrile;

[0076] Gradient elution program:

[0077]

[0078] Flow rate: 1.0ml / min;

[0079] Column temperature: 30°C;

[0080] Detection wavelength: 245nm;

[0081] Injection volume: 50 μl;

[0082] Take each solution and inject it for testing according to the above chromatographic conditions. Figures 3 to 5 In the system diagram, 4.862min is the mesityl oxide peak, and 10.151min is the phorone peak; the blank solvent and adjacent chromatographic peaks do not interfere with mesityl oxide and phorone, the separation degree meets the requirements, and the specificity is good; the external standard method is used to calculate the peak area, and the mesityl oxide and phorone peaks can be quantitatively detected in the test solution.

Claims

1. A method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride, characterized in that: High performance liquid chromatography was used with water and acetonitrile as mobile phases for gradient elution, which was achieved by the following steps: (1) Chromatographic conditions: A chromatographic column using octadecylsilane bonded silica as a filler; Water was used as mobile phase A and acetonitrile as mobile phase B, and the elution was performed by a gradient elution program; (2) Solution preparation: Reference solution: weigh mesityl oxide and phorone reference substances, add solvent to make a solution containing 0.005 μg to 0.5 μg of phorone and mesityl oxide per 1 mL; Test solution: Take gemcitabine hydrochloride and add solvent to make a solution of 1 mg / ml to 50 mg / ml.

2. The method for measuring mesityl oxide and phorone residues in gemcitabine hydrochloride according to claim 1, characterized in that: The chromatographic column is an Inertsil ODS-3, 4.6 mm×250 mm, 5 μm or an Inertsil ODS-3v, 4.6 mm×250 mm, 5 μm chromatographic column.

3. The method for measuring mesityl oxide and phorone residues in gemcitabine hydrochloride according to claim 1, characterized in that: The gradient elution procedure is:

4. The method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride according to claim 1, characterized in that: The detection column temperature is 15°C to 40°C, the flow rate is 0.5ml / min to 2ml / min, the detection wavelength is 200nm to 300nm, and the injection volume is 10μl to 100μl.

5. The method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride according to claim 1, characterized in that: The solvent used to prepare the reference solution and the test solution is acetonitrile with a volume concentration of 10% to 90%.

6. The method for determining mesityl oxide and phorone residues in gemcitabine hydrochloride according to claim 5, characterized in that: The concentration of the reference solution is 0.05 μg / ml, and the concentration of the test solution is 10 mg / ml.